齐普罗夫洛克萨辛与勒沃弗洛克萨辛在血造干细胞移植中的预防:一个随机试验
Shatha Farhan1, Izabela Mazur1, Susan Hartzell2
1Stem Cell Transplant and Cellular Therapy, Henry Ford Health, Detroit, MI, USA.
概括
列沃素和西普罗素在血造干细胞移植 (SCT) 患者的血流感染预防方面表现出类似的疗效. 然而,勒沃素预防导致SCT后的肺炎较少.
科学领域:
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
- 临床试验 临床试验
背景情况:
- 造血干细胞移植 (SCT) 需要有效的预防策略来预防感染.
- 细菌性血流感染 (BSI) 在SCT接受者中是一个重大问题.
- 将诺基诺抗生素用于预防的比较对于优化患者的治疗结果至关重要.
研究的目的:
- 为了比较西普罗夫洛克萨与勒沃弗洛克萨在SCT接受者的预防疗法的疗效和安全性.
- 确定血流细菌感染 (BSI) 的发病率作为主要结局.
- 评估二次结果,包括肺炎,移植和死亡率.
主要方法:
- 这是一项前性随机试验,涉及亨利福特健康的308名SCT患者.
- 患者被分为1:1接受西普罗夫洛克萨或勒沃弗洛克萨预防治疗.
- 主要终点是SCT后60天内BSI的发生率.
主要成果:
- 齐普罗夫洛克萨辛和莱沃弗洛克萨辛组之间BSI发生率没有显著差异 (两组均为11.7%).
- 肺炎发生的频率更高,在西普罗夫洛克萨辛组 (18%) 与勒沃弗洛克萨辛组 (7%).
- 在中性粒细胞移植,发烧,C. difficile感染,生存或停留时间方面没有观察到差异.
结论:
- 齐普罗夫洛克萨和莱沃弗洛克萨都是SCT接受者的有效预防药物.
- 列沃素预防与SCT后60天内肺炎发病率较低有关.
- 这些发现表明,对于减少呼吸道并发症,可能更喜欢使用利沃素.
相关概念视频
01:22Bone Marrow Sampling and Transplants
321
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
321
01:01Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K